These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25894088)

  • 1. From Bioequivalence to Biosimilarity: The Rise of a Novel Regulatory Framework.
    Karalis VD
    Drug Res (Stuttg); 2016 Jan; 66(1):1-6. PubMed ID: 25894088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union.
    van Aerts LA; De Smet K; Reichmann G; van der Laan JW; Schneider CK
    MAbs; 2014; 6(5):1155-62. PubMed ID: 25517301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scientific factors and current issues in biosimilar studies.
    Chow SC; Endrenyi L; Lachenbruch PA; Mentré F
    J Biopharm Stat; 2014; 24(6):1138-53. PubMed ID: 25098559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonparametric tests for evaluation of biosimilarity in variability of follow-on biologics.
    Zhang N; Yang J; Chow SC; Chi E
    J Biopharm Stat; 2014; 24(6):1239-53. PubMed ID: 25036940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The similarity question for biologicals and non-biological complex drugs.
    Crommelin DJ; Shah VP; Klebovich I; McNeil SE; Weinstein V; Flühmann B; Mühlebach S; de Vlieger JS
    Eur J Pharm Sci; 2015 Aug; 76():10-7. PubMed ID: 25912826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparability and biosimilarity: considerations for the healthcare provider.
    Lee JF; Litten JB; Grampp G
    Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of the EU Biosimilar Framework: Past and Future.
    Wolff-Holz E; Tiitso K; Vleminckx C; Weise M
    BioDrugs; 2019 Dec; 33(6):621-634. PubMed ID: 31541400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demonstration of biosimilarity, extrapolation of indications and other challenges related to biosimilars in Europe.
    Tsiftsoglou AS; Trouvin JH; Calvo G; Ruiz S
    BioDrugs; 2014 Dec; 28(6):479-86. PubMed ID: 25391420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab.
    Ebbers HC; van Meer PJ; Moors EH; Mantel-Teeuwisse AK; Leufkens HG; Schellekens H
    Drug Discov Today; 2013 Sep; 18(17-18):872-9. PubMed ID: 23688584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars: are they bioequivalent?
    Gomollón F
    Dig Dis; 2014; 32 Suppl 1():82-7. PubMed ID: 25531357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
    Scott BJ; Klein AV; Wang J
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comprehensive Overview on Biosimilars.
    Kadam V; Bagde S; Karpe M; Kadam V
    Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.